291 related articles for article (PubMed ID: 12777059)
1. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML; Shiota FM; McNeel DG; Knutson KL
Immunobiology; 2003; 207(3):179-86. PubMed ID: 12777059
[TBL] [Abstract][Full Text] [Related]
2. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
Ferrone CR; Perales MA; Goldberg SM; Somberg CJ; Hirschhorn-Cymerman D; Gregor PD; Turk MJ; Ramirez-Montagut T; Gold JS; Houghton AN; Wolchok JD
Clin Cancer Res; 2006 Sep; 12(18):5511-9. PubMed ID: 17000687
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination.
Kwissa M; Kröger A; Hauser H; Reimann J; Schirmbeck R
J Mol Med (Berl); 2003 Feb; 81(2):91-101. PubMed ID: 12601525
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
7. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine.
Hartoonian C; Ebtekar M; Soleimanjahi H; Karami A; Mahdavi M; Rastgoo N; Azadmanesh K
Cytokine; 2009 Apr; 46(1):43-50. PubMed ID: 19278866
[TBL] [Abstract][Full Text] [Related]
9. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
10. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines.
Iwasaki A; Stiernholm BJ; Chan AK; Berinstein NL; Barber BH
J Immunol; 1997 May; 158(10):4591-601. PubMed ID: 9144471
[TBL] [Abstract][Full Text] [Related]
11. Plasmid DNA vaccines are effective in the absence of IFNgamma.
Hassett DE; Zhang J; Whitton JL
Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
[TBL] [Abstract][Full Text] [Related]
16. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
18. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
19. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
20. Effect of plasmid DNA encoding the porcine granulocyte-macrophage colony-stimulating factor on antigen-presenting cells in pigs.
Melkebeek V; Van den Broeck W; Verdonck F; Goddeeris BM; Cox E
Vet Immunol Immunopathol; 2008 Oct; 125(3-4):354-60. PubMed ID: 18762341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
